Alpine Woods Capital Investors’s Heron Therapeutics HRTX Stock Holding History

Alpine Woods Capital Investors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-10,000	Closed	-$190K	–	435
2016 Q1	$190K	Hold	10,000	–	–	0.01%	396
2015 Q4	$267K	Hold	10,000	–	–	0.01%	392
2015 Q3	$244K	Hold	10,000	–	–	0.01%	425
2015 Q2	$312K	Buy	+10,000	New	+$188K	0.02%	382

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alpine Woods Capital Investors's HRTX Position: Q2 2016 in Review

Alpine Woods Capital Investors sold out of Heron Therapeutics (HRTX) in Q2 2016, closing a stake of 10,000 shares — an estimated $190K sold.

Alpine Woods Capital Investors first reported a position in HRTX in Q2 2015 and held it in 4 quarters. The position peaked at $312K in Q2 2015. 92 funds tracked by Wall St. Rank hold HRTX as of Q2 2016.

Alpine Woods Capital Investors reported no remaining Heron Therapeutics position as of Q2 2016 after selling out during the quarter.
Alpine Woods Capital Investors sold 10,000 Heron Therapeutics shares in Q2 2016, an estimated $190K.
Alpine Woods Capital Investors first reported a position in Heron Therapeutics in Q2 2015 and held it in 4 quarters.
Alpine Woods Capital Investors's Heron Therapeutics position peaked at $312K in Q2 2015.
92 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2016.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2016, filed 10 Aug 2016.